scholarly journals Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial

2011 ◽  
Vol 53 (10) ◽  
pp. 977-984 ◽  
Author(s):  
A. P. Phyo ◽  
K. M. Lwin ◽  
R. N. Price ◽  
E. A. Ashley ◽  
B. Russell ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Plasmodium Vivax ◽  
Vivax Malaria ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Plasmodium Vivax Malaria

scholarly journals Pengaruh suplementasi seng dan vitamin B6 terhadap kadar hemoglobin, hematokrit dan indeks eritrosit pasien malaria vivax yang anemia

2016 ◽  
Vol 5 (1) ◽  
pp. 20-25
Author(s):  
Sofiyetti Sofiyetti ◽  
Edi Dharmana ◽  
M. Zen Rahfiludin ◽  
Nyoman Suci W ◽  
Diana Nur Afifah
Keyword(s):  
Plasmodium Vivax ◽  
Vivax Malaria ◽  
Vitamin B6 ◽  
Aminolevulinic Acid ◽  
Controlled Trial ◽  
Hemoglobin Level ◽  
T Test ◽  
Control Group ◽  
Significant Difference ◽  
Plasmodium Vivax Malaria

Background: Zinc supplementation decrease the risk of malaria parasitaemia, increasing ferritin serum level and hemoglobin in patients with malaria. Zinc influence the activity of aminolevulinic acid dehydratase (ALAD) an enzymes that catalizes heme synthesize. Vitamin B6 in pyridoxal 5-phosphate (PLP) from has a role in alpha-aminolevulinic acid (ALA) formation, which is the precursor of heme in hemoglobin. PLP also inhibit the growth of the malaria parasite.Objective: The objective was to analyze the effect of zinc and vitamin B6 supplementation on hemoglobin level, hematocrit and erythrocyte indexs (MCV, MCH and MCHC) of anemic Plasmodium vivax malaria patients.Methods: Double Blind Randomised Controlled Trial with pre and post test design. 30 subjects were divided into two groups: the suplementation group were given zinc 1x10 mg/day with vitamin B6 1x5 mg/day and the control group were given a placebo for 30 days. Data analysis by paired t-test, independent t-test and Mann Whitney.Results: There was an increase in Hb levels in the suplementation group (p=0.0001), the control group (p=0.001) and there was a significant difference on the increase between the two groups (p=0.020). Hematocrit significant increase only in the suplementation group (p=0.0001). There were no differences on erythrocyte index parameter in both groups.Conclusion: Zinc and vitamin B6 supplementation of for 30 days increase the hemoglobin level, hematocrit and there were no effect on erythrocyte indexs of anemic Plasmodium vivax malaria patients.

scholarly journals Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial

2016 ◽  
Vol 10 (10) ◽  
pp. e0005070 ◽  
Author(s):  
Myriam Arévalo-Herrera ◽  
Juan M. Vásquez-Jiménez ◽  
Mary Lopez-Perez ◽  
Andrés F. Vallejo ◽  
Andrés B. Amado-Garavito ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Plasmodium Vivax ◽  
Protective Efficacy ◽  
Controlled Trial ◽  
Randomized Controlled

scholarly journals A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Makoto Saito ◽  
Verena I. Carrara ◽  
Mary Ellen Gilder ◽  
Aung Myat Min ◽  
Nay Win Tun ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Pregnant Women ◽  
Falciparum Malaria ◽  
Vivax Malaria ◽  
Controlled Trial ◽  
Artemisinin Resistance ◽  
Antimalarial Treatment ◽  
Randomized Controlled ◽  
Link Type ◽  
In Pregnancy

Abstract Background Artemisinin and artemisinin-based combination therapy (ACT) partner drug resistance in Plasmodium falciparum have spread across the Greater Mekong Subregion compromising antimalarial treatment. The current 3-day artemether-lumefantrine regimen has been associated with high treatment failure rates in pregnant women. Although ACTs are recommended for treating Plasmodium vivax malaria, no clinical trials in pregnancy have been reported. Methods Pregnant women with uncomplicated malaria on the Thailand-Myanmar border participated in an open-label randomized controlled trial comparing dihydroartemisinin-piperaquine (DP), artesunate-mefloquine (ASMQ) and a 4-day artemether-lumefantrine regimen (AL+). The primary endpoint for P. falciparum infections was the PCR-corrected cure rate and for P. vivax infections was recurrent parasitaemia, before delivery or day 63, whichever was longer, assessed by Kaplan-Meier estimate. Results Between February 2010 and August 2016, 511 pregnant women with malaria (353 P. vivax, 142 P. falciparum, 15 co-infections, 1 Plasmodium malariae) were randomized to either DP (n=170), ASMQ (n=169) or AL+ (n=172) treatments. Successful malaria elimination efforts in the region resulted in premature termination of the trial. The majority of women had recurrent malaria (mainly P. vivax relapses, which are not prevented by these treatments). Recurrence-free proportions (95% confidence interval [95% CI]) for vivax malaria were 20.6% (5.1–43.4) for DP (n=125), 46.0% (30.9–60.0) for ASMQ (n=117) and 28.7% (10.0–50.8) for AL+ (n=126). DP and ASMQ provided longer recurrence-free intervals. PCR-corrected cure rates (95% CI) for falciparum malaria were 93.7% (81.6–97.9) for DP (n=49), 79.6% (66.1–88.1) for AMSQ (n=55) and 87.5% (74.3–94.2) for AL+ (n=50). Overall 65% (85/130) of P. falciparum infections had Pfkelch13 propeller mutations which increased over time and recrudescence occurred almost exclusively in them; risk ratio 9.42 (95% CI 1.30–68.29). Among the women with falciparum malaria, 24.0% (95% CI 16.8–33.6) had P. vivax parasitaemia within 4 months. Nausea, vomiting, dizziness and sleep disturbance were more frequent with ASMQ. Miscarriage, small-for-gestational-age and preterm birth did not differ significantly among the treatment groups, including first trimester exposures (n=46). Conclusions DP was well tolerated and safe, and was the only drug providing satisfactory efficacy for P. falciparum-infected pregnant woman in this area of widespread artemisinin resistance. Vivax malaria recurrences are very common and warrant chloroquine prophylaxis after antimalarial treatment in this area. Trial registration ClinicalTrials.gov identifier NCT01054248, registered on 22 January 2010.

Sign in / Sign up

Export Citation Format

Share Document